IκBNS regulates interleukin-6 production and inhibits neointimal formation after vascular injury in mice

Cardiovascular Research

Volumn 93, Issue 2, 2012, Pages 371-379

  Niida, Tomiharu ^a   Isoda, Kikuo ^a   Kitagaki, Manabu ^a   Ishigami, Norio ^a   Adachi, Takeshi ^a   Matsubara, Osamu ^a   Takeda, Kiyoshi ^b   Kishimoto, Tadamitsu ^b   Ohsuzu, Fumitaka ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

I BNS; Interleukin 6; Neointimal formation; Nuclear factor B; Vascular injury

Indexed keywords

I KAPPA B; I KAPPA B DELTA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD VESSEL INJURY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMORAL ARTERY; HYPERPLASIA; INFLAMMATION; MALE; MOUSE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; ROTATOR CUFF INJURY; VASCULAR SMOOTH MUSCLE; WILD TYPE; WOUND HEALING;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; CHOLESTEROL; INTERLEUKIN-6; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; NEOINTIMA; PROTEINS; TOLL-LIKE RECEPTOR 4;

EID: 84856190908     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr323     Document Type: Article

References (39)

1. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R et al. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 1996;97:1715-1722. (Pubitemid 26105480)
2. Landry DB, Couper LL, Bryant SR, Lindner V. Activation of the NF-kappa B and I kappa B system in smooth muscle cells after rat arterial injury: induction of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1. Am J Pathol 1997; 151:1085-1095. (Pubitemid 27424318)
3. Kearney M, Pieczek A, Haley L, Losordo DW, Andres V, Schainfeld R et al. Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation 1997; 95:1998-2002. (Pubitemid 27184264)
4. Yamamoto M, Takeda K. Role of nuclear IkappaB proteins in the regulation of host immune responses. J Infect Chemother 2008;14:265-269.
5. Kuwata H, Matsumoto M, Atarashi K, Morishita H, Hirotani T, Koga R et al. IkappaBNS inhibits induction of a subset of Toll-like receptor-dependent genes and limits inflammation. Immunity 2006;24:41-51. (Pubitemid 43077199)
6. Murabito JM, Keyes MJ, Guo CY, Keaney JF Jr, Vasan RS, D'Agostino RB Sr et al. Cross-sectional relations of multiple inflammatory biomarkers to peripheral arterial disease: the Framingham Offspring Study. Atherosclerosis 2009;203:509-514.
7. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation 2005; 112:976-983. (Pubitemid 41170265)
8. Luc G, Bard JM, Juhan-Vague I, Ferrieres J, Evans A, Amouyel P et al.; PRIME Study Group. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol 2003;23:1255-1261. (Pubitemid 36871282)
9. Empana JP, Jouven X, Canouï-Poitrine F, Luc G, Tafflet M, Haas B et al. C-reactive protein, interleukin 6, fibrinogen and risk of sudden death in European middle-aged men: the PRIME study. Arterioscler Thromb Vasc Biol 2010;30:2047-2052.
10. Isoda K, Nishikawa K, Kamezawa Y, Yoshida M, Kusuhara M, Moroi M et al. Osteopontin plays an important role in the development of medial thickening and neointimal formation. Circ Res 2002;91:77-82. (Pubitemid 34778945)
11. Isoda K, Sawada S, Ayaori M, Matsuki T, Horai R, Kagata Y et al. Deficiency of interleukin-1 receptor antagonist deteriorates fatty liver and cholesterol metabolism in hypercholesterolemic mice. J Bio Chem 2005;280:7002-7009. (Pubitemid 40341256)
12. Kobayashi M, Inoue K, Warabi E, Minami T, Kodama T. A simple method of isolating mouse aortic endothelial cells. J Atheroscler Thromb 2005;12:138-142.
13. Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2007;2:329-333. (Pubitemid 47040047)
14. Hedrick CC, Castellani LW, Warden CH, Puppione DL, Lusis AJ. Influence of mouse apolipoprotein A-II on plasma lipoproteins in transgenic mice. J Biol Chem 1993;268: 20676-20682. (Pubitemid 23278985)
15. Axmann R, Böhm C, Krönke G, Zwerina J, Smolen J, Schett G. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum 2009;60:2747-2756.
16. Bellas RE, Lee JS, Sonenshein GE. Expression of a constitutive NF-kappa B-like activity is essential for proliferation of cultured bovine vascular smooth muscle cells. J Clin Invest 1995;96:2521-2527.
17. Breuss JM, Cejna M, Bergmeister H, Kadl A, Baumgartl G, Steurer S et al. Activation of nuclear factor-kappa B significantly contributes to lumen loss in a rabbit iliac artery balloon angioplasty model. Circulation 2002;105:633-638. (Pubitemid 34123440)
18. Ohtani K, Egashira K, Nakano K, Zhao G, Funakoshi K, Ihara Y et al. Stent-based local delivery of nuclear factor-kappaB decoy attenuates in-stent restenosis in hypercholesterolemic rabbits. Circulation 2006;114:2773-2779. (Pubitemid 46018279)
19. Egashira K, Suzuki J, Ito H, Aoki M, Isobe M, Morishita R. Long-term follow up of initial clinical cases with NF-kappaB decoy oligodeoxynucleotide transfection at the site of coronary stenting. J Gene Med 2008;10:805-809. (Pubitemid 352003923)
20. Valen G, Yan ZQ, Hansson GK. Nuclear factor kappa-B and the heart. J Am Coll Cardiol 2001;38:307-314. (Pubitemid 32721754)
21. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-126.
22. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001; 107:7-11. (Pubitemid 32047405)
23. Collins T, Cybulsky MI. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 2001;107:255-264. (Pubitemid 32157955)
24. Wang D, Liu Z, Li Q, Karpurapu M, Kundumani-Sridharan V, Cao H et al. An essential role for gp130 in neointima formation following arterial injury. Circ Res 2007;100: 807-816. (Pubitemid 46555685)
25. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001;104:1188-1193. (Pubitemid 32830406)
26. Bowen-Pope DF, Malpass TW, Foster DM, Ross R. Platelet-derived growth factor in vivo: levels, activity, and rate of clearance. Blood 1984;64:458-469. (Pubitemid 14051334)
27. Loppnow H, Libby P. Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. J Clin Invest 1990;85:731-738. (Pubitemid 20087475)
28. Ikeda U, Ikeda M, Oohara T, Oguchi A, Kamitani T, Tsuruya Y et al. Interleukin 6 stimulates growth of vascular smooth muscle cells in a PDGF-dependent manner. Am J Physiol 1991;260:H1713-H1717.
29. Akira S, Uematsu S, Takeuchi O. Patogen recognition and innate immunity. Cell 2006; 124:783-801.
30. Maffia P, Grassia G, Di Meglio P, Carnuccio R, Berrino L, Garside P et al. Neutralization of interleukin-18 inhibits neointimal formation in a rat model of vascular injury. Circulation 2006;114:430-437. (Pubitemid 44264825)
31. Takagi N, Mihara M, Moriya Y, Nishimoto N, Yoshizaki K, Kishimoto T et al. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum 1998;41:2117-2121. (Pubitemid 29009369)
32. Iwanami K, Matsumoto I, Tanaka-Watanabe Y, Inoue A, Mihara M, Ohsugi Y et al. Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase. Arthritis Rheum 2008;58:754-763. (Pubitemid 351364873)
33. Jones G, Ding C. Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord 2010;3:81-89.
34. Seki Y, Kai H, Shibata R, Nagata T, Yasukawa H, Yoshimura A et al. Role of the JAK/STAT pathway in rat carotid artery remodeling after vascular injury. Circ Res 2000;87: 12-18. (Pubitemid 30456929)
35. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008;54:24-38. (Pubitemid 351182593)
36. Hojo Y, Ikeda U, Katsuki T, Mizuno O, Fukazawa H, Kurosaki K et al. Interleukin 6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis. Heart 2000;84:83-87. (Pubitemid 30429230)
37. Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 1999;19:2364-2367. (Pubitemid 29477837)
38. Zuliani G, Volpato S, Blè A, Bandinelli S, Corsi AM, Lauretani F et al. High interleukin-6 plasma levels are associated with low HDL-C levels in community-dwelling older adults: the InChianti study. Atherosclerosis 2007;192: 384-390. (Pubitemid 46735937)
39. Seino Y, Ikeda U, Ikeda M, Yamamoto K, Misawa Y, Hasegawa T et al. Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine 1994;6: 87-91. (Pubitemid 24120205)